Physician profile
Gerald Borrelli
NPI 1871599084
$189,714.21
in general payments reported to CMS, 2019-2025
19 companies · $4,774 in 2025
The $4,774 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $28K · 2021: $25K · 2022: $25K · 2023: $34K · 2024: $22K · 2025: $4,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $2,839 · Food and Beverage: $2,410 · Education: $76.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,935.00 |
| Travel and Lodging | $2,838.81 |
| Food and Beverage | $2,410.09 |
| Education | $76.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $123,198.99 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $49,862.91 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $15,053.13 | 2019 | |
| Nxstage Medical, INC. | $328.44 | 2021-2025 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $269.79 | 2019-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $222.82 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $151.42 | 2022-2023 | |
| Akebia Therapeutics INC | $116.87 | 2024-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $100.55 | 2022-2025 | Thiola, Filspari |
| Aurinia Pharma U.S., INC. | $85.24 | 2021-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $58.68 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $44.45 | 2023 | Jesduvroq, Benlysta |
| Alexion Pharmaceuticals, INC. | $37.26 | 2022 | |
| Novo Nordisk INC | $36.41 | 2024-2025 | Ozempic |
| Lundbeck LLC | $33.99 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.91 | 2019 | |
| Horizon Therapeutics Plc | $30.62 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $26.35 | 2023 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $23.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Borrelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.